Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes
Background: The FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease
Progression in Diabetic Kidney Disease) evaluated the effect of the nonsteroidal, selective …
Progression in Diabetic Kidney Disease) evaluated the effect of the nonsteroidal, selective …
Regulation of miRNAs by natural antioxidants in cardiovascular diseases: Focus on SIRT1 and eNOS
Y Lee, E Im - Antioxidants, 2021 - mdpi.com
Cardiovascular diseases (CVDs) are the most common cause of morbidity and mortality
worldwide. The potential benefits of natural antioxidants derived from supplemental nutrients …
worldwide. The potential benefits of natural antioxidants derived from supplemental nutrients …
Role of hypertension in kidney transplant recipients
C Loutradis, P Sarafidis, S Marinaki, M Berry… - Journal of human …, 2021 - nature.com
Cardiovascular events are one of the leading causes of mortality in kidney transplant
recipients. Hypertension is the most common comorbidity accompanying chronic kidney …
recipients. Hypertension is the most common comorbidity accompanying chronic kidney …
Trimethylamine N-oxide mediated Y-box binding protein-1 nuclear translocation promotes cell cycle progression by directly downregulating Gadd45a expression in a …
L Wang, N Zhu, J Jia, L Gu, Y Du, G Tang, X Wang… - Life Sciences, 2021 - Elsevier
Aims Cell cycle arrest plays critical roles in preventing renal tubular epithelial cell (RTEC)
injury and maladaptation after the onset of chronic kidney disease (CKD), but the underlying …
injury and maladaptation after the onset of chronic kidney disease (CKD), but the underlying …
Association of kidney functions with a cascade of care for diabetes and hypertension in two geographically distinct Indian cohorts
S Khandpur, M Bhardwaj, A Awasthi… - Diabetes Research and …, 2021 - Elsevier
Abstract Aim Type 2 diabetes (T2DM) and hypertension (HTN) are the main modifiable risk
factors of chronic kidney disease (CKD), among the known traditional and non-traditional …
factors of chronic kidney disease (CKD), among the known traditional and non-traditional …
Therapeutic effects of allopurinol and topiroxostat in chronic kidney disease patients with hyperuricemia
A Kaiga, T Ishimitsu, H Satonaka… - Dokkyo Journal of …, 2021 - dmu.repo.nii.ac.jp
Patients with chronic kidney disease (CKD) are at high risk for developing cardiovascular
diseases, and hyperuricemia is associated with the progression of renal dysfunction and the …
diseases, and hyperuricemia is associated with the progression of renal dysfunction and the …
[PDF][PDF] Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease
RK Halimi, PB Mark, A Persu, P Rossignol10, M Luis - 2021 - researchgate.net
Diabetic kidney disease develops in about 40% of patients with diabetes and is the
commonest cause of chronic kidney disease worldwide. Patients with chronic kidney …
commonest cause of chronic kidney disease worldwide. Patients with chronic kidney …
[PDF][PDF] Influence of Chronic Kidney Disease on Coronary Plaque Components in Coronary Artery Disease Patients with both Diabetes Mellitus and Hypertension
重本英二， シゲモトエイジ - 2021 - fukuoka-u.repo.nii.ac.jp
Influence of Chronic Kidney Disease on Coronary Plaque Components in Coronary Artery
Disease Patients with both Diabetes Mellitu Page 1 1 Influence of Chronic Kidney Disease on …
Disease Patients with both Diabetes Mellitu Page 1 1 Influence of Chronic Kidney Disease on …
[PDF][PDF] Factors relating to vascular damage in patients on continuous ambulatory peritoneal dialysis
植松麻友 - 2021 - dmu.repo.nii.ac.jp
Chronic kidney disease (CKD) patients, especially the patients with end-stage renal disease
(ESRD) who are on dialysis therapy are at high risk for developing cardiovascular diseases …
(ESRD) who are on dialysis therapy are at high risk for developing cardiovascular diseases …